Advertisement
Singapore markets close in 30 minutes
  • Straits Times Index

    3,177.29
    +5.36 (+0.17%)
     
  • Nikkei

    40,003.60
    +263.20 (+0.66%)
     
  • Hang Seng

    16,529.48
    -207.62 (-1.24%)
     
  • FTSE 100

    7,726.42
    +3.87 (+0.05%)
     
  • Bitcoin USD

    63,684.67
    -3,685.18 (-5.47%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • S&P 500

    5,149.42
    +32.33 (+0.63%)
     
  • Dow

    38,790.43
    +75.63 (+0.20%)
     
  • Nasdaq

    16,103.45
    +130.25 (+0.82%)
     
  • Gold

    2,152.30
    -12.00 (-0.55%)
     
  • Crude Oil

    82.51
    -0.21 (-0.25%)
     
  • 10-Yr Bond

    4.3400
    0.0000 (0.00%)
     
  • FTSE Bursa Malaysia

    1,547.59
    -6.05 (-0.39%)
     
  • Jakarta Composite Index

    7,351.63
    +49.18 (+0.67%)
     
  • PSE Index

    6,848.43
    -4.86 (-0.07%)
     

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Emergent BioSolutions Inc. - EBS

NEW YORK, June 14, 2021 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Emergent BioSolutions Inc. (“Emergent” or the “Company”) (NYSE: EBS). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.

The investigation concerns whether Emergent and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action]

On March 31, 2021, the New York Times published an article reporting on the accidental contamination at an Emergent manufacturing plant in Baltimore of coronavirus vaccines developed by Johnson & Johnson and AstraZeneca PLC. According to reporting by the Associated Press, the Emergent factory where the contamination occurred had a series of lapses observed by the U.S. Food and Drug Administration in April 2020.

ADVERTISEMENT

On this news, Emergent’s stock price fell $12.45 per share, or 13.4%, to close at $80.46 per share on April 1, 2021.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com

CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
888-476-6529 ext. 7980